Martin Samuel Bates 4
4 · Celldex Therapeutics, Inc. · Filed Jan 4, 2024
Insider Transaction Report
Form 4
Martin Samuel Bates
SVP AND CFO
Transactions
- Exercise/Conversion
Common Stock
2024-01-02$2.78/sh+10,750$29,885→ 35,128 total - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2024-01-02−10,750→ 0 totalExercise: $2.78Exp: 2029-06-19→ Common Stock (10,750 underlying)
Footnotes (1)
- [F1]As of June 19, 2023, the option is fully vested.